IGHV3-43

Across TCGA pan-cancer cohorts, IGHV3-43 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGHV3-43 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IGHV3-43 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-43 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, BLCA, and LUSC are the cancer types where IGHV3-43 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.061	0.731	<.001	24	view →
BLCA	DFS	Median	All	0.139	0.626	.010	18	view →
LUSC	DFS	Median	All	0.196	0.750	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.546	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IGHV3-43–STAD (OS)

Open the STAD breakdown →